IBDEI0BZ ; ; 20-MAY-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;OCT 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,5679,0)
 ;;=V10.21^^41^488^61
 ;;^UTILITY(U,$J,358.3,5679,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5679,1,4,0)
 ;;=4^V10.21
 ;;^UTILITY(U,$J,358.3,5679,1,5,0)
 ;;=5^H/O Laryngeal Cancer
 ;;^UTILITY(U,$J,358.3,5679,2)
 ;;=^295214
 ;;^UTILITY(U,$J,358.3,5680,0)
 ;;=284.2^^41^488^106
 ;;^UTILITY(U,$J,358.3,5680,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5680,1,4,0)
 ;;=4^284.2
 ;;^UTILITY(U,$J,358.3,5680,1,5,0)
 ;;=5^Myelophthisic Anemia
 ;;^UTILITY(U,$J,358.3,5680,2)
 ;;=^334037
 ;;^UTILITY(U,$J,358.3,5681,0)
 ;;=202.40^^41^488^76
 ;;^UTILITY(U,$J,358.3,5681,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5681,1,4,0)
 ;;=4^202.40
 ;;^UTILITY(U,$J,358.3,5681,1,5,0)
 ;;=5^Hairy Cell Leukemia,Unspecified site
 ;;^UTILITY(U,$J,358.3,5681,2)
 ;;=^69587
 ;;^UTILITY(U,$J,358.3,5682,0)
 ;;=287.49^^41^488^118
 ;;^UTILITY(U,$J,358.3,5682,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5682,1,4,0)
 ;;=4^287.49
 ;;^UTILITY(U,$J,358.3,5682,1,5,0)
 ;;=5^Thrombocytopenia,Drug Induced
 ;;^UTILITY(U,$J,358.3,5682,2)
 ;;=^339610
 ;;^UTILITY(U,$J,358.3,5683,0)
 ;;=180.9^^41^488^29
 ;;^UTILITY(U,$J,358.3,5683,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5683,1,4,0)
 ;;=4^180.9
 ;;^UTILITY(U,$J,358.3,5683,1,5,0)
 ;;=5^Ca Cervix
 ;;^UTILITY(U,$J,358.3,5683,2)
 ;;=^267214
 ;;^UTILITY(U,$J,358.3,5684,0)
 ;;=203.02^^41^488^104
 ;;^UTILITY(U,$J,358.3,5684,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5684,1,4,0)
 ;;=4^203.02
 ;;^UTILITY(U,$J,358.3,5684,1,5,0)
 ;;=5^Multiple Myeloma,In Relapse
 ;;^UTILITY(U,$J,358.3,5684,2)
 ;;=^336462
 ;;^UTILITY(U,$J,358.3,5685,0)
 ;;=204.02^^41^488^2
 ;;^UTILITY(U,$J,358.3,5685,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5685,1,4,0)
 ;;=4^204.02
 ;;^UTILITY(U,$J,358.3,5685,1,5,0)
 ;;=5^ALL,In Relapse
 ;;^UTILITY(U,$J,358.3,5685,2)
 ;;=^336465
 ;;^UTILITY(U,$J,358.3,5686,0)
 ;;=204.12^^41^488^17
 ;;^UTILITY(U,$J,358.3,5686,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5686,1,4,0)
 ;;=4^204.12
 ;;^UTILITY(U,$J,358.3,5686,1,5,0)
 ;;=5^CLL,In Relapse
 ;;^UTILITY(U,$J,358.3,5686,2)
 ;;=^336466
 ;;^UTILITY(U,$J,358.3,5687,0)
 ;;=204.20^^41^488^114
 ;;^UTILITY(U,$J,358.3,5687,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5687,1,4,0)
 ;;=4^204.20
 ;;^UTILITY(U,$J,358.3,5687,1,5,0)
 ;;=5^Subacute LL w/o Remission
 ;;^UTILITY(U,$J,358.3,5687,2)
 ;;=^336852
 ;;^UTILITY(U,$J,358.3,5688,0)
 ;;=204.21^^41^488^116
 ;;^UTILITY(U,$J,358.3,5688,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5688,1,4,0)
 ;;=4^204.21
 ;;^UTILITY(U,$J,358.3,5688,1,5,0)
 ;;=5^Subacute LL,In Remission
 ;;^UTILITY(U,$J,358.3,5688,2)
 ;;=^267526
 ;;^UTILITY(U,$J,358.3,5689,0)
 ;;=204.22^^41^488^115
 ;;^UTILITY(U,$J,358.3,5689,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5689,1,4,0)
 ;;=4^204.22
 ;;^UTILITY(U,$J,358.3,5689,1,5,0)
 ;;=5^Subacute LL,In Relapse
 ;;^UTILITY(U,$J,358.3,5689,2)
 ;;=^336467
 ;;^UTILITY(U,$J,358.3,5690,0)
 ;;=205.02^^41^488^5
 ;;^UTILITY(U,$J,358.3,5690,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5690,1,4,0)
 ;;=4^205.02
 ;;^UTILITY(U,$J,358.3,5690,1,5,0)
 ;;=5^AML,In Relapse
 ;;^UTILITY(U,$J,358.3,5690,2)
 ;;=^336470
 ;;^UTILITY(U,$J,358.3,5691,0)
 ;;=205.12^^41^488^20
 ;;^UTILITY(U,$J,358.3,5691,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5691,1,4,0)
 ;;=4^205.12
 ;;^UTILITY(U,$J,358.3,5691,1,5,0)
 ;;=5^CML,In Relapse
 ;;^UTILITY(U,$J,358.3,5691,2)
 ;;=^336471
 ;;^UTILITY(U,$J,358.3,5692,0)
 ;;=284.81^^41^488^14
 ;;^UTILITY(U,$J,358.3,5692,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,5692,1,4,0)
 ;;=4^284.81
 ;;^UTILITY(U,$J,358.3,5692,1,5,0)
 ;;=5^Aplastic Anemia d/t Drugs
 ;;^UTILITY(U,$J,358.3,5692,2)
 ;;=^335245
